Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Vascular Biogenics Ltd. (NASDAQ: VBLT).

Full DD Report for VBLT

You must become a subscriber to view this report.


Recent News from (NASDAQ: VBLT)

VBL Therapeutics Announces Publication of Positive New Data on its Lecinoxoid Drug Candidates for the Treatment of Renal Fibrosis
These data, together with positive preclinical NASH data previously presented, support the potential of VBL’s lecinoxoid pipeline Recently granted US patent provides patent protection for lecinoxoids treatment of fibrosis until at least November 2035 and supports potential part...
Source: GlobeNewswire
Date: August, 30 2018 07:00
VBL Therapeutics (VBLT) CEO Dror Harats on Q2 2018 Results - Earnings Call Transcript
VBL Therapeutics (VBLT) Q2 2018 Results Earnings Conference Call August 16, 2018, 08:30 AM ET Executives Michael Wood - LifeSci Advisors Dror Harats - CEO Amos Ron - CFO Analysts Swayampakula Ramakanth - H.C. Wainwright Presentation Operator Good day, ladies and ...
Source: SeekingAlpha
Date: August, 16 2018 12:25
VBL Therapeutics net loss improves in Q2
VBL Therapeutics ( VBLT ) Q2 results : Revenues: $0.2M; Net Loss: ($4.1M) (+16.3%); Loss Per Share: ($0.13) (+27.8%); Quick Assets: $58.5M (+6.9%). More news on: VBL Therapeutics, Healthcare stocks news, Earnings news and commentary, , Read more ...
Source: SeekingAlpha
Date: August, 16 2018 07:16
VBL Therapeutics beats by $0.05, misses on revenue
VBL Therapeutics (NASDAQ: VBLT ): Q2 EPS of -$0.13 beats by $0.05 . More news on: VBL Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 16 2018 07:01
VBL Therapeutics Announces Second Quarter 2018 Financial Results
Conference Call and Webcast at 8:30am Eastern Time Today VBL is well capitalized, cash sufficient for more than 3 years, beyond key inflection points VBL continues development of VB-111 for Ovarian Cancer with the OVAL Phase 3 trial ongoing, and intends to explore VB-111 activity i...
Source: GlobeNewswire
Date: August, 16 2018 07:00
VBL Therapeutics to Report Second Quarter 2018 Financial Results on August 16
TEL AVIV, Israel, Aug. 01, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio ...
Source: GlobeNewswire
Date: August, 01 2018 08:00
Publication by VBL Therapeutics Highlights MOSPD2 as a Potential New Target for Breast Cancer Therapy
Paper on Role of MOSPD2 in Metastatic Breast Cancer Published in International Journal of Cancer TEL AVIV, Israel, July 10, 2018 (GLOBE NEWSWIRE) --   VBL Therapeutics  (NASDAQ:VBLT) today announced the publication of data on the potential role of MOSPD2 in metastatic breas...
Source: GlobeNewswire
Date: July, 10 2018 08:00
VBL Therapeutics Announces Closing of $15.5 Million Registered Direct Offering
TEL AVIV, Israel, June 27, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics  (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer,  today announced the closing of its previously announce...
Source: GlobeNewswire
Date: June, 27 2018 16:01
VBL Therapeutics Announces $15.5 Million Registered Direct Offering Priced At-the-Market
TEL AVIV, Israel, June 26, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics  (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer,  today announced that it has entered into definitive ag...
Source: GlobeNewswire
Date: June, 26 2018 08:57
Breakfast Technical Briefing on Tesaro and Three Other Additional Biotech Stocks
Stock Research Monitor: TLGT, VBLT, andVTGN LONDON, UK / ACCESSWIRE / June 20, 2018 / If you want a free Stock Review on TSRO sign up now at www.wallstequities.com/registration . Today's attention is redirected to Biotechnology, which is a highly volatile and unpredictable sector due t...
Source: ACCESSWIRE IA
Date: June, 20 2018 07:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-101.171.201.221.1071,157
2018-12-071.201.17221.221.1646,476
2018-12-061.201.201.221.1838,761
2018-12-051.251.191.261.1927,136
2018-12-041.251.201.261.1925,556

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-108,08131,25425.8559Cover
2018-12-0718,59926,64369.8082Short
2018-12-0613,06416,47879.2815Short
2018-12-046034,24314.2116Cover
2018-12-033,40020,70516.4212Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VBLT.


About Vascular Biogenics Ltd. (NASDAQ: VBLT)

Logo for Vascular Biogenics Ltd. (NASDAQ: VBLT)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: VBLT)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 17 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 27 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: March, 15 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 15 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 08 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: February, 26 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: February, 21 2018
      Notice from the SEC of registration effectiveness
      Filing Type: EFFECTFiling Source: edgar
      Filing Date: January, 04 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: January, 03 2018
      Amendment to a previously filed F-3
      Filing Type: F-3/AFiling Source: edgar
      Filing Date: January, 02 2018

       

       


      Daily Technical Chart for (NASDAQ: VBLT)

      Daily Technical Chart for (NASDAQ: VBLT)


      Stay tuned for daily updates and more on (NASDAQ: VBLT)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: VBLT)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VBLT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of VBLT and does not buy, sell, or trade any shares of VBLT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/